论文部分内容阅读
目的建立一种改良的血清１，２５－（ＯＨ）２维生素Ｄ３即１，２５二羟基胆钙甾醇（１，２５－ｄｉｈｙｄｒｏｃｈｏｌｅ－ｃａｌｃｉｆｅｒｅｌ，ＤＨＣＣ）超微量放射受体检测技术（ＲＲＡ），对原发性骨质疏松症血清的ＤＨＣＣ含量进行检测。方法用非均相核素交换法制备了３Ｈ－ＤＨＣＣ，应用超速离心技术制备胞浆受体蛋白，改进提取与纯化手段，建立ＤＨＣＣ放射受体分析方法，检测了骨质疏松症患者血样。结果完成灵敏度、精密度、准确度、稳定性及特异性等方法学技术指标，经分析检测的原发性骨质疏松症患者血清，ＤＨＣＣ含量明显低于正常老年对照组（Ｐ＜０．０５）。结论ＤＨＣＣ降低是发生骨质疏松症的重要原因之一。
Objective To establish a modified serum 1,25- (OH) 2 vitamin D3 (1,25-dihydrochole-calciferel, DHCC) ultra-trace radioactive receptor assay (RRA) The level of DHCC in sera from osteoporosis was measured. Methods 3H-DHCC was prepared by heterogeneous nuclear exchange method. Cytoplasmic receptor protein was prepared by ultracentrifugation, and the extraction and purification methods were improved. The method of radio-immunoassay for DHCC was established to detect the blood samples of patients with osteoporosis. Results The methodological indexes of sensitivity, precision, accuracy, stability and specificity were completed. The contents of serum and DHCC in patients with primary osteoporosis detected by analysis were significantly lower than those in normal control group (P <0.05 ). Conclusions Decreased DHCC is one of the important causes of osteoporosis.